Drug Discovery - Medicine.net

Drug Discovery

Sub Categories on Drug Discovery

{{items.name}}

Latest Articles

No OS benefit for concurrent and consolidative durvalumab vs. consolidation alone in unresectable stage 3 NSCLC: Trial

No OS benefit for concurrent and consolidative durvalumab vs. consolidation alone in unresectable stage 3 NSCLC: Trial

Updated on: October 05,2025

No OS benefit for concurrent and consolidative durvalumab vs. consolidation alone in unresectable stage 3 NSCLC: Trial

No OS benefit for concurrent and consolidative durvalumab vs. consolidation alone in unresectable stage 3 NSCLC: Trial

Updated on:October 05,2025

Medical infusion bags can release microplastics, study shows

Medical infusion bags can release microplastics, study shows

Updated on: April 18,2025

Medical infusion bags can release microplastics, study shows

Medical infusion bags can release microplastics, study shows

Updated on:April 18,2025

Cancer study identifies why patients do not respond to personalized immune therapy, sparking new vaccine

Cancer study identifies why patients do not respond to personalized immune therapy, sparking new vaccine

Updated on: October 06,2025

Cancer study identifies why patients do not respond to personalized immune therapy, sparking new vaccine

Cancer study identifies why patients do not respond to personalized immune therapy, sparking new vaccine

Updated on:October 06,2025

Ivonescimab + chemotherapy improves progression-free survival in patients with EGFR+ NSCLC

Ivonescimab + chemotherapy improves progression-free survival in patients with EGFR+ NSCLC

Updated on: October 03,2025

Ivonescimab + chemotherapy improves progression-free survival in patients with EGFR+ NSCLC

Ivonescimab + chemotherapy improves progression-free survival in patients with EGFR+ NSCLC

Updated on:October 03,2025

Novel spatial immune-based risk prediction platform can predict hepatocellular carcinoma recurrence

Novel spatial immune-based risk prediction platform can predict hepatocellular carcinoma recurrence

Updated on: April 22,2025

Novel spatial immune-based risk prediction platform can predict hepatocellular carcinoma recurrence

Novel spatial immune-based risk prediction platform can predict hepatocellular carcinoma recurrence

Updated on:April 22,2025

Lung cancer rewires immune cells in bone marrow to weaken body's defenses

Lung cancer rewires immune cells in bone marrow to weaken body's defenses

Updated on: October 02,2025

Lung cancer rewires immune cells in bone marrow to weaken body's defenses

Lung cancer rewires immune cells in bone marrow to weaken body's defenses

Updated on:October 02,2025

UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms

UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms

Updated on: October 06,2025

UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms

UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms

Updated on:October 06,2025

More diverse investigators could help diversify clinical trials

More diverse investigators could help diversify clinical trials

Updated on: April 18,2025

More diverse investigators could help diversify clinical trials

More diverse investigators could help diversify clinical trials

Updated on:April 18,2025

Study reveals split opinions on long-term opioid use for chronic pain

Study reveals split opinions on long-term opioid use for chronic pain

Updated on: March 27,2025

Study reveals split opinions on long-term opioid use for chronic pain

Study reveals split opinions on long-term opioid use for chronic pain

Updated on:March 27,2025

Clinical trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

Clinical trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

Updated on: October 05,2025

Clinical trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

Clinical trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

Updated on:October 05,2025

Categories

Allergy&Clinical immunology

Anesthesiology & Pain

Cardiovascular Diseases

Diabetes & Endocrinology

Emergency Medicine & Critical Care

Family Medicine

Gastroenterology

General Surgery

Hematology&Oncology

Infectious Diseases

Nephrology & Urology

Orthopedics & Sports medicine

Plastic Surgery

Psychiatry & Mental Health

Public Health & Prevention